JB Chemicals & Pharmaceuticals Second Quarter Results Immediate Release: JB Chemicals & Pharmaceuticals reported second quarter results for the current fiscal year, showing significant growth in profit and revenue. The company announced its financial results on November 6, 2024, with revenue increasing by 13.48% year-on-year and profit increasing by 15.92% year-on-year. However, compared with the previous quarter, revenue fell slightly by 0.38% and profit fell by 1.28%.
The company’s selling, general and administrative expenses increased by 2.19% from the previous quarter and a significant increase of 15.03% from the same period last year. The increase in expenses led to a decrease in operating income, which dropped 4.57% from the previous quarter, but still increased by 8.17% year-on-year.
Earnings per share (EPS) for the quarter were $In November, the annual increase was 15.3%. Despite mixed results, JB Chemicals & Pharmaceuticals has shown resilience, returning -0.1% last week, 4.57% over the past six months, and 15.76% year-to-date.
Currently, JB Chemicals & Pharmaceuticals has a market capitalization of $29,209.98 Crore, a new 52-week high $2030 and minimum $1371. The stock’s performance has caught the attention of analysts, with 1 analysts rating it a Strong Sell, 2 recommending a Hold, 2 recommending a Buy, and 6 assigning it a Strong Buy rating.
As of November 7, 2024, analysts are unanimously recommending Buy, indicating a positive outlook for the company’s future performance.
JB Chemical & Pharmaceutical Finance
| period | Q2 | Q1 | Quarterly growth | Q2 | annual growth |
|---|---|---|---|---|---|
| total revenue | 1000.62 | 1004.4 | -0.38% | 881.74 | +13.48% |
| Total Selling/General/Administrative Expenses | 170.57 | 166.91 | +2.19% | 148.28 | +15.03% |
| Depreciation/amortization | 41.88 | 40.78 | +2.7% | 32.17 | +30.18% |
| total operating expenses | 771.98 | 764.81 | +0.94% | 670.37 | +15.16% |
| operating income | 228.64 | 239.59 | -4.57% | 211.37 | +8.17% |
| net income before tax | 236.53 | 239.84 | -1.38% | 208.66 | +13.36% |
| net income | 174.57 | 176.83 | -1.28% | 150.59 | +15.92% |
| Diluted normalized earnings per share | 11 | 11.16 | -1.43% | 9.54 | +15.3% |
